Publications by authors named "Howard Chilcoat"

Claim this Profile
R
Re: Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States.
Angela M DeVeaugh-Geiss, Howard D Chilcoat

Int J Drug Policy· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.
Michael K Gilbert, Ashlynn R Daughton, Howard D Chilcoat, Celine M Laffont, Stephanie Strafford

J Med Internet Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain severity contributes to worse outcomes in opioid use disorder recovery than pain status.
William H Craft, Candice L Craft, Allison N Tegge, Liqa N Athamneh, Jeffrey S Stein, Howard D Chilcoat

Drug Alcohol Depend· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010‒2017).
Karilynn M Rockhill, Gabrielle E Bau, Angela DeVeaugh-Geiss, Howard Chilcoat, Richard Dart

J Am Coll Emerg Physicians Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids.
Emily A Miller, Angela M DeVeaugh-Geiss, Howard D Chilcoat

Drug Alcohol Depend Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Struggling With Recovery From Opioids: Who Is at Risk During COVID-19?
Diana R Keith, Allison N Tegge, Jeffrey S Stein, Liqa N Athamneh, William H Craft, Howard D Chilcoat

J Addict Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life.
William H Craft, Hwasoo Shin, Allison N Tegge, Diana R Keith, Liqa N Athamneh, Howard D Chilcoat

Addiction· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019.
Stephen C Ijioma, Howard D Chilcoat, Angela M DeVeaugh-Geiss

J Subst Use Addict Treat· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.
Brent Boyett, Vijay R Nadipelli, Caitlyn T Solem, Howard Chilcoat, Warren K Bickel

J Addict Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
Madelyn J McDonald, Angela M DeVeaugh-Geiss, Howard D Chilcoat, Jennifer R Havens

J Addict Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study" [Drug Alcohol Depend., 234 (2022), 109389].
William H Craft, Allison N Tegge, Diana R Keith, Hwasoo Shin, Jacob Williams, Howard D Chilcoat

Drug Alcohol Depend· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.
William H Craft, Allison N Tegge, Diana R Keith, Hwasoo Shin, Jacob Williams, Howard D Chilcoat

Drug Alcohol Depend· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of non-prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration.
Jan Gryczynski, Joshua D Lee, Kristi Dusek, Ryan McDonald, Anjalee Sharma, Howard D Chilcoat

J Subst Abuse Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
Walter Ling, Vijay R Nadipelli, Arnie P Aldridge, Naoko A Ronquest, Caitlyn T Solem, Howard Chilcoat

J Addict Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration.
Laura B Monico, Jan Gryczynski, Joshua D Lee, Kristi Dusek, Ryan McDonald, Howard Chilcoat

J Subst Abuse Treat· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
Howard D Chilcoat, Halle R Amick, Molly R Sherwood, Kelly E Dunn

J Subst Abuse Treat· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the use of diverted buprenorphine.
Theodore J Cicero, Matthew S Ellis, Howard D Chilcoat

Drug Alcohol Depend· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records.
Carla A Green, Nancy A Perrin, Shannon L Janoff, Cynthia I Campbell, Howard D Chilcoat

Pharmacoepidemiol Drug Saf· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis.
Bobbi Jo H Yarborough, Scott P Stumbo, Shannon L Janoff, Micah T Yarborough, Dennis McCarty, Howard D Chilcoat

Drug Alcohol Depend· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Howard D Chilcoat, Paul M Coplan, Venkatesh Harikrishnan, Louis Alexander

Drug Alcohol Depend· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
Shannon L Janoff, Nancy A Perrin, Paul M Coplan, Howard D Chilcoat, Cynthia I Campbell

BMC Pharmacol Toxicol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit among commercially insured individuals in the United States (2008-2013).
Angela DeVeaugh-Geiss, Aditi Kadakia, Howard Chilcoat, Louis Alexander, Paul Coplan

J Pain· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
Nelson E Sessler, Jerod M Downing, Hrishikesh Kale, Howard D Chilcoat, Todd F Baumgartner

Pharmacoepidemiol Drug Saf· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Jennifer R Havens, Carl G Leukefeld, Angela M DeVeaugh-Geiss, Paul Coplan, Howard D Chilcoat

Drug Alcohol Depend· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
Emily C McNaughton, Paul M Coplan, Ryan A Black, Sarah E Weber, Howard D Chilcoat

J Med Internet Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis